From the same Jan 2019 news release and alluded to
Post# of 36537
(Total Views: 202)
Posted On: 11/07/2019 8:40:46 PM
From the same Jan 2019 news release and alluded to in the recent CC about other things Olaregen is working on:
"Excellagen activates platelets, triggering the release of essential growth factors and providing a structural scaffold for cellular infiltration and migration, this process significantly accelerates the growth of granulation tissue. Excellagen's flowable fibrillar collagen formulation is topically applied through pre-filled sterile syringes, and is designed for application at once weekly intervals.
Additionally, Excellagen can serve as an enabling delivery platform delivering peptides, small molecule drugs, DNA biologics, antimicrobials, stem cells, and exosomes. Exosomes, commonly referred to as extracellular vesicles are the residual components of stem cells responsible for cell-to-cell signaling, the most significant aspect of a cell’s function. Combined with certain tissue types, Excellasome can provide a significant advance in regenerative medicine.
Olaregen’s pipeline will focus on developing Excellasome for the regeneration of bones, joints and cartilage. R&D efforts will address the use of Excellasome in the treatment osteoarthritis, rheumatoid arthritis, cartilage repair, and plantar fasciitis."
-the market for the above is 100's and 100's (as Joe is fond of saying) times larger than for wound care.
"Excellagen activates platelets, triggering the release of essential growth factors and providing a structural scaffold for cellular infiltration and migration, this process significantly accelerates the growth of granulation tissue. Excellagen's flowable fibrillar collagen formulation is topically applied through pre-filled sterile syringes, and is designed for application at once weekly intervals.
Additionally, Excellagen can serve as an enabling delivery platform delivering peptides, small molecule drugs, DNA biologics, antimicrobials, stem cells, and exosomes. Exosomes, commonly referred to as extracellular vesicles are the residual components of stem cells responsible for cell-to-cell signaling, the most significant aspect of a cell’s function. Combined with certain tissue types, Excellasome can provide a significant advance in regenerative medicine.
Olaregen’s pipeline will focus on developing Excellasome for the regeneration of bones, joints and cartilage. R&D efforts will address the use of Excellasome in the treatment osteoarthritis, rheumatoid arthritis, cartilage repair, and plantar fasciitis."
-the market for the above is 100's and 100's (as Joe is fond of saying) times larger than for wound care.
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼